Status:
ACTIVE_NOT_RECRUITING
Efficacy and Safety of High-Dose Rate Brachytherapy with Immunotherapy and Chemotherapy As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
The First People's Hospital of Neijiang
Conditions:
Advanced Stage NSCLC
Second-line Treatment
Eligibility:
All Genders
18-90 years
Brief Summary
This is a single-center, retrospective, propensity score-matched study exploring the efficacy and safety of high-dose rate (HDR) brachytherapy combined with immune checkpoint inhibitors (ICIs) and che...
Detailed Description
Study Title: Exploring the Efficacy and Safety of High-Dose Rate Brachytherapy Combined with Immunotherapy and Chemotherapy as a Second-Line Treatment in Patients with Advanced Non-Small Cell Lung Can...
Eligibility Criteria
Inclusion
- Diagnosis of advanced Non-Small Cell Lung Cancer (NSCLC),Likely stage IIIB-IV, though specific staging is not mentioned
- Patients requiring second-line treatment Implying progression after first-line therapy
- Age: Adults (specific age range not provided, but typically 18 years or older)
- Presence of measurable disease according to RECIST v1.1 criteria
- Adequate organ function (specific parameters not provided, but typically included in such studies)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (not explicitly stated, but common in similar studies)
Exclusion
- Presence of targetable driver mutations (e.g., EGFR, ALK, ROS1, BRAF)
- Prior treatment with HDR brachytherapy for the current disease
- Contraindications to immunotherapy or chemotherapy
- Severe comorbidities that would preclude safe administration of study treatments
- Brain metastases, unless treated and stable (not explicitly stated, but common in similar studies)
- Participation in another clinical trial with an investigational agent
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06518018
Start Date
September 1 2023
End Date
September 1 2025
Last Update
July 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second People's Hospital of Neijiang
Neijiang, Sichuan, China, 641000